{'fraction_non_alphanumeric': 0.027472527472527472, 'fraction_numerical': 0.005494505494505495, 'mean_word_length': 6.197368421052632, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Enhanced venous thrombus resolution in plasminogen activator inhibitor type‐2 deficient mice

The resolution of deep vein thrombosis requires an inflammatory response and mobilization of proteases, such as urokinase‐type plasminogen activator (uPA) and matrix metalloproteinases (MMPs), to degrade the thrombus and remodel the injured vein wall. Plasminogen activator inhibitor type 2 (PAI‐2) is a serine protease inhibitor (serpin) with unique immunosuppressive and cell survival properties that was originally identified as an inhibitor of uPA.